Abiopharma

🔍 Albert Benjamin (Executive)

Company: Health Catalyst, Inc. (HCAT)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 1,124 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: A | equity_swap_involved: false | shares_owned_after: 1,459,102.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 310 shares of Common Stock at $1.345 per share (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: false | shares_owned_after: 1,458,792.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents an award of 1,124 performance-based restricted units of the Issuer ("PRSUs") pursuant to the Issuer's 2019 Stock Option and Incentive Plan, based upon the Issuer's satisfaction of certain performance criteria for the fiscal year ended December 31, 2025, approved by the Issuer's board of directors on April 29, 2026. Each PRSU represents a contingent right to receive one share of the Issuer's common stock.
• F2: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Issuer's Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.